A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
暂无分享,去创建一个
Philip J Rosenfeld | Janet L Davis | Sander R. Dubovy | William Feuer | P. Rosenfeld | W. Feuer | H. Flynn | S. Dubovy | Janet L. Davis | Geeta A. Lalwani | Harry W Flynn | Geeta A Lalwani | A. Fung | Sander R Dubovy | Anne E Fung | Maria Esquiabro | Stephen Michels | S. Michels | Maria Esquiabro
[1] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[2] J. Vander,et al. Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration , 2008 .
[3] Peter K Kaiser,et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.
[4] Mark Michels,et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.
[5] J S Sunness,et al. Measuring geographic atrophy in advanced age-related macular degeneration. , 1999, Investigative ophthalmology & visual science.
[6] N. Bressler,et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.
[7] P. Kertes,et al. Photodynamic Therapy of Subfoveal Choroidal Neovascularization with Verteporfin , 2004 .
[8] S. Harding. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .
[9] William J Feuer,et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[10] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[11] J. Vander,et al. Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .
[12] Jens Dreyhaupt,et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. , 2007, American journal of ophthalmology.
[13] J S Sunness,et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. , 1999, Ophthalmology.
[14] R. Spaide. Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.